Oncology News

Treating patients with hepatitis C and hepatocellular carcinoma or decompensated cirrhosis with all-oral direct-acting antiviral therapy prior to liver transplantation had highly effective results and was more cost effective than treating post-LT, according to simulated results of a recent study.

Direct-acting antiviral treatment cured HCV in most patients with prior hepatocellular carcinoma and in almost all patients who received a liver transplant as treatment for HCC, according to a recently published study.

NeuroVive announced two research agreements designed to further develop the company’s new drug compounds in the pipeline for the treatment of nonalcoholic steatohepatitis and hepatocellular carcinoma, according to a press release.

Sorafenib improved OS among patients with hepatocellular carcinoma who were hepatitis C positive but hepatitis B negative, suggesting that the beneficial effects of sorafenib may be based on hepatitis status, according to results of a meta-analysis.

A phase 3 study of tivantinib as second-line treatment for hepatocellular carcinoma failed to meet its primary endpoint of improved OS, according to the drug’s manufacturers.

Theodore H. Welling, III, MD, has been named director of a new liver tumor program at NYU Langone’s Perlmutter Cancer Center.

Gold standard monitoring for hepatocellular carcinoma in patients with cirrhosis, as recommended by guidelines, was more cost-effective and beneficial to patients compared with real-life monitoring, according to the results of a simulation study.

Risks for hepatocellular carcinoma and non-Hodgkin lymphoma appeared greater among women who had undergone a blood transfusion more than 5 years earlier, according to results of a prospective study conducted in the United Kingdom.

The risk for hepatocellular carcinoma was low among patients with cirrhosis, with a 10-year incidence of 4% or lower, according to the results of a U.K. population-based cohort study.

Stivarga was safe and improved overall survival for patients with unresectable hepatocellular carcinoma, according to data from the RESORCE clinical trial recently published in The Lancet.